{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:06:22Z","timestamp":1779195982511,"version":"3.51.4"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaad.2025.12.046","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:14:51Z","timestamp":1765988091000},"page":"1911-1912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["When profit shapes prescriptions: The dilemma of insurer-driven biologic switching"],"prefix":"10.1016","volume":"94","author":[{"given":"Dev","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kateryna","family":"Karpoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jaad.2025.12.046_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.3804","article-title":"Pharmacy benefit managers: history, business practices, economics, and policy","volume":"4","author":"Mattingly","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.046_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-017-0693-5","article-title":"Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: a practical overview","volume":"77","author":"Hindryckx","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.046_bib3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.18553\/jmcp.2025.24317","article-title":"Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: implications of a formulary change","volume":"31","author":"Fendrick","year":"2025","journal-title":"J Manag Care Specialty Pharm"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.046_bib4","first-page":"97","article-title":"Short-term costs associated with non-medical switching in autoimmune conditions","volume":"37","author":"Gibofsky","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.12.046_bib5","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.37765\/ajmc.2022.89246","article-title":"Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative review","volume":"28","author":"Merola","year":"2022","journal-title":"Am J Manag Care"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:08:06Z","timestamp":1779192486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225034279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0190962225034279"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.046","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When profit shapes prescriptions: The dilemma of insurer-driven biologic switching","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}